AstraZeneca PLC, Max Planck Institute To Create Satellite Chemistry Unit
Published: Jul 09, 2014
AstraZeneca announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a "satellite unit" in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.
The new collaboration will see AstraZeneca scientists working side-by-side with researchers from the Max Planck Institute of Molecular Physiology, in the Department of Chemical Biology, led by Prof. Herbert Waldmann. The satellite unit will focus on novel chemistry and chemical biology in areas of new modality chemistry such as stabilized peptides, macrocycles and conjugation chemistry.
Help employers find you! Check out all the jobs and post your resume.